Liz Collins
Executive Director, Pharmaceutical Sciences, Pfizer
Liz first joined Pfizer as part of her undergraduate degree program, working in early drug product development. Upon completion of her Bachelors and Ph.D. degrees, she re-joined Pfizer in 2002 as a formulation lead for the Biologics group in the UK and led a team developing monoclonal antibody formulations for early clinical studies. Since that time, Liz has held a number of positions across the pharmaceutical sciences business in scientific leadership and management roles. In early 2021, Liz progressed into an Executive Director role with matrix accountability for the pharmaceutical sciences business in the anti-infective category. This included leading the pharmaceutical development of Paxlovid™ (Covid anti-viral).
In addition to these project responsibilities, Liz leads the global pharmaceutical sciences (PS) equity council and sits on the global PS leadership team. Having been a member of the MMIP skills group for a number of years, Liz took over leadership of this group at the end of 2022 and joined the MMIP LT. Liz also represents ABPI as a board member of Cogent Skills.
Liz has a BSc from Loughborough University in Medicinal and Pharmaceutical Chemistry, and a Ph.D. from the Welsh School of Pharmacy in Non-viral Gene Delivery to the Lung.
In addition to these project responsibilities, Liz leads the global pharmaceutical sciences (PS) equity council and sits on the global PS leadership team. Having been a member of the MMIP skills group for a number of years, Liz took over leadership of this group at the end of 2022 and joined the MMIP LT. Liz also represents ABPI as a board member of Cogent Skills.
Liz has a BSc from Loughborough University in Medicinal and Pharmaceutical Chemistry, and a Ph.D. from the Welsh School of Pharmacy in Non-viral Gene Delivery to the Lung.